| Identification | Back Directory | [Name]
Dianhydrogalactitol | [CAS]
23261-20-3 | [Synonyms]
VAL083
VAL-083
VAL 083
NSC-132313
Dulcitol diepoxide
Dianhydrogalactitol
Dianhydrodulcitolum
5,6-Diepoxydulcitol
1,2:5,6-Diepoxydulcitol
1,2,5,6-DIANHYDRODULCITOL
1,2:5,6-Dianhydrogalactitol
Dianhydrodulcitol USP/EP/BP
Galactitol, 1,2:5,6-dianhydro-
1,2:5,6-Diepoxyhexane-3,4-diol
1,2-Di(oxiranyl)ethylene glycol
VAL083; VAL083; VAL083; DIANHYDRODULCITOL; DIANHYDROGALACTITOL; DULCITOL DIEPOXIDE; | [Molecular Formula]
C6H10O4 | [MDL Number]
MFCD01725532 | [MOL File]
23261-20-3.mol | [Molecular Weight]
146.14 |
| Chemical Properties | Back Directory | [Melting point ]
96.5-98.5 °C | [Boiling point ]
185.74°C (rough estimate) | [density ]
1.567 | [refractive index ]
1.4310 (estimate) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
13.53±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Dulcitol Diepoxide is a cytostatic drug. Dulcitol Diepoxide can be used for treatment of leukemia, lung cancer, multiple myeloma, and nasopharyngeal carcinoma. | [Biological Activity]
val-083 is a bi-functional alkylating agent, with potential antitumor activity.val-083 can cross the blood brain barrier and appears to be selective for tumor cells. val-083 alkylates and crosslinks dna which ultimately inhibit the proliferation of cancer cells. val-083 does not show cross-resistance to other conventional chemotherapeutic agents. the half-life of val-083 in the brain is long. val-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors. | [in vitro]
VAL-083 is an alkylating agent that creates N7 methylation on DNA. VAL-083 suppresses U251 and SF188 cell growth and induces apoptosis after 72 h. | [in vivo]
VAL-083 (Dianhydrogalactitol; 25, 50, 100 μg/mL) dose-dependently inhibits angiogenesis in zebrafish model. VAL-083 considerably reduces VEGF, VEGFR2, and FGF2 expression at 25 μg/mL, and further causes reduction in FGFR2 expression at 50 μg/mL. It (1,2:5,6-dianhydrogalactitol; 5 mg/kg, iv, twice per week for 6 weeks) significantly blocks the growth of LN229 cells in mice with the relative tumor growth rate (T/C) of 22.38%, and the tumor growth inhibitory rate (TGI) of 83.58%. Moreover, VAL-083 dramatically activates the CDC25C-CDK1 cascade in the xenografted tumor moedl. | [target]
DNA | [References]
http://www. delmarpharma.com/product_development_programs/val083/ |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.is0513.com/ShowSupplierProductsList15748/0.htm |
|